Welcome to our dedicated page for Network 1 Techno news (Ticker: NTIP), a resource for investors and traders seeking the latest updates and insights on Network 1 Techno stock.
Network-1 Technologies, Inc. (NYSE American: NTIP) specializes in the development, licensing, and protection of intellectual property (IP) rights. The company collaborates with inventors and patent owners to facilitate the development and monetization of patented technologies. Currently, Network-1 owns 102 U.S. patents and 15 international patents, covering various telecommunications, data networking technologies, document stream operating systems, and media content identification technologies.
Network-1's strategy focuses on acquiring and investing in high-quality patents with significant licensing potential. It actively pursues licensing opportunities for its intellectual property assets. Its core patent portfolios include the Cox, M2M/IoT, HFT, Mirror Worlds, and Remote Power patents. Notably, the Remote Power Patent has generated over $188 million in licensing revenue since May 2007, while the Mirror Worlds Patent Portfolio has brought in $47.15 million to date.
Network-1 continues to expand its patent portfolio. The recent issuance of U.S. Patent No. 11,916,893 enhances its M2M/IoT Patent Portfolio, which now includes 37 issued U.S. patents and several pending applications. These patents cover enabling technologies for eSIMs, 5G network authentication, and modern Internet transport layer security solutions.
Financially, Network-1 reported a net revenue of $2.601 million for the year ended December 31, 2023, primarily from litigation settlements related to its Remote Power Patent. Despite a net loss of $1.457 million, the company's robust cash position of $43.394 million and marketable securities of $43.067 million ensure sufficient liquidity for future operations.
In addition to its core business, Network-1 has a significant investment in ILiAD Biotechnologies, LLC, owning approximately 6.8% of the clinical-stage biotechnology firm. ILiAD's BPZE1 vaccine for whooping cough has shown promising results in Phase 2b clinical trials.
Network-1 also implements a Share Repurchase Program and a consistent dividend policy. The company has repurchased over 9.72 million shares since the program's inception and continues to pay semi-annual cash dividends of $0.05 per share.
FAQ
What is the current stock price of Network 1 Techno (NTIP)?
What is the market cap of Network 1 Techno (NTIP)?
What does Network-1 Technologies, Inc. do?
What are Network-1's core business areas?
What are Network-1's most notable patents?
How much revenue has Network-1's Remote Power Patent generated?
What financial condition is Network-1 in?
Does Network-1 pay dividends?
What is the Share Repurchase Program?
What recent achievements has Network-1 made?
What is Network-1's investment in ILiAD Biotechnologies?
Where is Network-1 Technologies, Inc. located?
